7th Jan 2014 08:40
LONDON (Alliance News) - ANGLE PLC said Tuesday it has appointed Dr Harold Swerdlow as a scientific adviser to the firm with immediate effect.
Swerdlow is head of research and development for the Wellcome Trust Sanger Institute in Cambridgeshire and is an expert in next-generation sequencing, said the firm. Previously, he was the Chief Technology Officer of Dolomite Ltd., a microfluidics and microfabrication company.
ANGLE is working on demonstrating the compatibility of the Parsortix circulating tumour cell harvesting capability, with the established molecular analysis platforms deployed by some of the world's largest medtech companies, and has identified this as a key area of commercialisation for the Parsortix system, said the company. The aim is that CTCs harvested from patient blood by the Parsortix system, the "liquid biopsy", are analysed for mutations and other important medical information on the medtech companies' existing platforms thereby greatly expanding their market application.
Founder and Chief Executive of the firm, Andrew Newland said, "We believe that next-generation sequencing is a core analytical technology, which will be fundamental to personalised cancer treatment in the future. Aligning the Parsortix cell-capture technology with next-generation sequencing is a key commercial objective."
Shares in ANGLE last traded at 82 pence per share.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle